TMED2 promotes epithelial ovarian cancer growth

Gong Shi-Peng; Chen Chun-Lin; Wu Huan; Meng Fan-Liang; Chen Yong-Ning; Zhang Ya-Di; Zhang Guang-Ping; Cai Ye-Ping

doi:10.18632/oncotarget.21593

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

TMED2 promotes epithelial ovarian cancer growth

Gong Shi-Peng _, Chen Chun-Lin, Wu Huan, Meng Fan-Liang, Chen Yong-Ning, Zhang Ya-Di, Zhang Guang-Ping and Cai Ye-Ping

PDF | HTML | How to cite

Oncotarget. 2017; 8:94151-94165. https://doi.org/10.18632/oncotarget.21593

Metrics: PDF 1694 views | HTML 2043 views | ?

Abstract

Gong Shi-Peng1,*, Chen Chun-Lin1,*, Wu Huan2,*, Meng Fan-Liang1, Chen Yong-Ning1, Zhang Ya-Di1, Zhang Guang-Ping3 and Cai Ye-Ping4

1Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P.R. China

2Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, P.R. China

3Department of Gynecology, People's Hospital of Huadu District, Guangzhou 510800, P.R. China

4Department of Gynecology, Maternal and Child Health Hospital of Duanzhou District, Zhaoqing 526000, P.R. China

*These authors have contributed equally to the study and should considered as co-first authors

Correspondence to:

Gong Shi-Peng, email: [email protected]

Keywords: epithelial ovarian cancer, TMED2, IGF1R, AKT, miR-30a

Received: August 06, 2017 Accepted: September 08, 2017 Published: October 06, 2017

ABSTRACT

TMED2 is involved in morphogenesis of the mouse embryo and placenta. We found that expression of TMED2 was higher in epithelial ovarian cancer tissues than normal ovarian tissues. Silencing TMED2 decreased cell proliferation, migration, and invasion. Ectopic expression of TMED2 increased cell proliferation, migration and invasion. Silencing TMED2 inhibited ovarian cancer growth in mice. Silencing TMED2 inhibited IGF2/IGF1R/PI3K/Akt pathway. In agreement, ectopically expressed TMED2 activated IGF2/IGF1R/PI3K/Akt pathway. Mechanistic study revealed that TMED2 directly binds to AKT2, thereby facilitating its phosphorylation. We also found that TMED2 increased IGF1R expression by competing for miR-30a. Thus, TMED2 is oncogenic and a potential target for epithelial ovarian cancer therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21593

Publication Alerts

Research Papers:

TMED2 promotes epithelial ovarian cancer growth

Abstract